Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation.
van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC, Boucher CA, Gratama JW, Budel LM, van der Holt B, van Loon AM, Löwenberg B, Verdonck LF, Cornelissen JJ. van Esser JW, et al. Among authors: gratama jw. Br J Haematol. 2001 Jun;113(3):814-21. doi: 10.1046/j.1365-2141.2001.02789.x. Br J Haematol. 2001. PMID: 11380475 Free article.
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ. van Esser JW, et al. Among authors: gratama jw. Blood. 2002 Jun 15;99(12):4364-9. doi: 10.1182/blood.v99.12.4364. Blood. 2002. PMID: 12036863 Free article. Clinical Trial.
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Löwenberg B, Verdonck LF, Cornelissen JJ. van Esser JW, et al. Among authors: gratama jw. Blood. 2001 Aug 15;98(4):972-8. doi: 10.1182/blood.v98.4.972. Blood. 2001. PMID: 11493441 Free article.
Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
Gadisseur AP, Gratama JW, Lamers C, van Esser JW, Bolhuis RL, Cornelissen JJ. Gadisseur AP, et al. Among authors: gratama jw. Bone Marrow Transplant. 1999 May;23(10):1013-7. doi: 10.1038/sj.bmt.1701755. Bone Marrow Transplant. 1999. PMID: 10373067
A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE, van der Holt B, Haze S, Braakman E, Gratama JW, Löwenberg B, Cornelissen JJ. Broers AE, et al. Among authors: gratama jw. Exp Hematol. 2005 Aug;33(8):912-9. doi: 10.1016/j.exphem.2005.05.005. Exp Hematol. 2005. PMID: 16038784 Free article.
315 results